OVERVIEW
Selonterra is a San Francisco Bay Area, venture capital-funded, biotechnology company.
Selonterra was founded on the premise that a disruptive approach is needed to address the unmet medical needs of Alzheimer's disease and Parkinson's disease.
Our Unique Approach
Selonterra develops therapeutics for Alzheimer's disease and Parkinson's disease by exploiting our breakthrough, novel mechanisms on genetics and gene regulatory networks.
Genetics plays a key role in Alzheimer's and Parkinson's diseases. However, the extensive body of information on disease-associated genes has not translated to therapeutics.
Selonterra's scientists discovered unexpected gene regulatory functions for key gene variants linked to Alzheimer's and Parkinson's diseases.
We found that these variants regulate the expresssion of genes in their genomic vicinity and that those genes and their encoded proteins offer new and unexploited molecular targets for drug discovery.
We target the function and expresssion of these proteins in our small molecule discovery programs to develop effective therapeutics.
All rights reserved © Selonterra, Inc., 2021